Lazard Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $249K | Sell |
27,854
-166,699
| -86% | -$1.49M | ﹤0.01% | 1651 |
|
|
2025
Q1 | $1.46M | Buy |
194,553
+33,037
| +20% | +$248K | ﹤0.01% | 1068 |
|
|
2024
Q4 | $1.21M | Buy |
161,516
+65,420
| +68% | +$492K | ﹤0.01% | 1071 |
|
|
2024
Q3 | $730K | Buy |
+96,096
| New | +$730K | ﹤0.01% | 1232 |
|
|
2024
Q2 | – | Sell |
-13,179
| Closed | -$66K | – | 2231 |
|
|
2024
Q1 | $66K | Sell |
13,179
-964
| -7% | -$4.83K | ﹤0.01% | 1657 |
|
|
2023
Q4 | $84K | Buy |
+14,143
| New | +$84K | ﹤0.01% | 1724 |
|
|
2023
Q2 | – | Sell |
-3,567
| Closed | -$29K | – | 2306 |
|
|
2023
Q1 | $29K | Hold |
3,567
| – | – | ﹤0.01% | 1947 |
|
|
2022
Q4 | $40K | Hold |
3,567
| – | – | ﹤0.01% | 1912 |
|
|
2022
Q3 | $44K | Hold |
3,567
| – | – | ﹤0.01% | 1846 |
|
|
2022
Q2 | $37K | Hold |
3,567
| – | – | ﹤0.01% | 1933 |
|
|
2022
Q1 | $57K | Buy |
+3,567
| New | +$57K | ﹤0.01% | 1675 |
|
|
2021
Q4 | – | Sell |
-3,238
| Closed | -$46K | – | 2291 |
|
|
2021
Q3 | $46K | Buy |
+3,238
| New | +$46K | ﹤0.01% | 1715 |
|
|
2020
Q2 | – | Sell |
-17,523
| Closed | -$35K | – | 1616 |
|
|
2020
Q1 | $35K | Buy |
+17,523
| New | +$35K | ﹤0.01% | 1305 |
|